Skip to main content

Hls Therapeutics Inc(HLS-T)
TSX

Today's Change
Real-Time Last Update
Day Low4.60
Day High4.95
Open:4.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Newswire.ca
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Newswire.ca
HLS Therapeutics Announces Fiscal 2023 Financial Results
Newswire.ca
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call
Newswire.ca
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
Newswire.ca
HLS Therapeutics Announces CFO Departure
Newswire.ca
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
Newswire.ca
HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid
Newswire.ca
HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference
Newswire.ca
HLS Therapeutics Announces Updates to its Credit Agreement
Newswire.ca
HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results
Newswire.ca
HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics Announces Updates to its Board of Directors
Newswire.ca
HLS Therapeutics Reports Annual Meeting Results
Newswire.ca
HLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of Directors
The Globe and Mail
HLS Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (HLS)
Newswire.ca
HLS Therapeutics Announces Q1 Fiscal 2023 Financial Results
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call
The Globe and Mail
HLS Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (HLS)
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Newswire.ca
HLS Therapeutics Announces CEO Transition
The Globe and Mail
HLS Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (HLS)
Baystreet
Stocks in play: HLS Therapeutics Inc.
Newswire.ca
HLS Therapeutics Announces Q4 and Fiscal 2022 Financial Results

Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.